Drugs Made In America Acquisition Corp. (DMAAR) Free Cash Flow (2025)

Drugs Made In America Acquisition (DMAAR) has reported Free Cash Flow for 1 consecutive years, with -$125180.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Free Cash Flow changed N/A year-over-year to -$125180.0; the trailing twelve-month figure through Dec 2025 stood at -$539187.0 (changed N/A YoY), and the FY2025 full-year result was -$539187.0, down 213.0% from the prior year.
• Free Cash Flow fell to -$125180.0 in Q4 2025 per DMAAR's latest filing, from -$56108.0 in the prior quarter.
• Across five years, Free Cash Flow topped out at -$56108.0 in Q3 2025 and bottomed at -$251244.0 in Q1 2025.